KORU Medical Systems, Inc. (KRMD)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$3.25+0.93%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
KORU Medical aims for 15-22% revenue growth in 2026. Gross margin is steady near 62%. Management targets positive adjusted EBITDA and cash flow this year. Recent M&A deals support growth and supply stability.
The company is still loss-making with no positive cash flow yet. Revenue growth and margin targets may be missed. New CEO transition and loan amendments add uncertainty.
The price is about 42% below our fair value near $8. Analysts expect 20% revenue growth, roughly in line with management targets. Our view is cautious given profitability risks.
Breaks if: gross margin falls below 61% in FY26
Sustain gross margin within the 61% to 64% range throughout fiscal year 2026 to support profitability.
Stated as a priority in 3 of last 3 quarters. Gross margin improved from 61.5% in 2026-Q1 to 65.1% in 2026-Q2, exceeding the guided range of 61% to 64%. Management has consistently reiterated this gross margin target and the trajectory shows delivering and slight improvement beyond guidance.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is characterized as a turnaround, as KRMD is working to improve its financial health after a period of losses. The current thesis state reflects a cautious optimism due to recent strong financial performance, but the company still faces significant risks.
The market currently prices KRMD at a premium compared to its peers, suggesting that investors have high expectations for its future performance. However, there is a notable expectations gap, indicating that the market may be overly optimistic about the company's ability to sustain its recent improvements.
Management has set clear priorities to achieve positive adjusted EBITDA and cash flow, with some progress noted in recent quarters. Revenue growth is on track, but the company remains loss-making, which adds to its risk profile.
The most important moves since the prior daily snapshot.
risk label changed from 'elevated' to 'high'.
Yes, our read has strengthened. The latest earnings beat supports a strong revenue growth outlook. The company aims for 15-22% revenue growth in 2026, reinforcing positive momentum. There are no current threats impacting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Raising full year 2026 gross margin to be between 62 - 64%”
“Reiterating full year 2026 gross margin between 61 - 63%”
“Reiterating full year gross margin guidance of 61% - 63%”
Breaks if: adjusted EBITDA and cash flow remain negative through FY26
Deliver positive adjusted EBITDA and positive cash flow for the full year 2026 as a key financial performance goal.
Stated as a priority in 3 of last 3 quarters. Adjusted EBITDA improved from $0.3 million in 2025-Q2 to $0.9 million in 2026-Q2, with positive cash flow from operations reported in 2026-Q1 and Q2. Management has consistently reiterated this goal and the trajectory is delivering positive adjusted EBITDA and improving cash flow.
“Reiterating positive adjusted EBITDA for the full year”
“Reiterating positive adjusted EBITDA and positive cash flow for the full year 2026”
“Positive adjusted EBITDA and positive cash flow for the full year 2026.”
Breaks if: YoY revenue growth falls below 15% in FY26
Grow net revenues by 15% to 22% in fiscal year 2026, driven by core domestic and international markets.
Stated as a priority in 3 of last 3 quarters. Revenue increased 18.2% year-over-year to $12.0 million in 2026-Q2 from $10.2 million in 2025-Q2, aligning with management's guidance of 15% to 22% growth for 2026. The trajectory is delivering consistent revenue growth as committed.
“Narrowing full year 2026 net revenues to be between $47.5 - $48.5 million, representing growth of 15% - 18%”
“Reiterating full year 2026 net revenues between $47.5 - $50.0 million representing growth of 15% - 22%”
“Initiating 2026 guidance to include net revenues of $47.5 - $50.0 million, representing growth of 15 – 22%”
The long-term thesis hinges on KRMD's ability to maintain its growth trajectory and achieve its financial targets. Key factors include the performance of sector bellwethers and the overall economic environment, particularly any signs of recession that could impact demand.
In the next 1 to 3 years, KRMD's success will depend on its execution of management priorities and external market conditions. Not investment advice.